BiOkuris

IBS is a public health problem that affects 10-20% of the population, predominantly affecting women in Europe and North America. With a peak level of frequency between the ages of 20 and 40, it causes young individuals to experience significantly disabling symptoms, resulting in a considerable reduction in their quality of life.

The physiopathology is complex and multifactorial, with existing treatments in Europe only providing a temporary relief of symptoms, without truly addressing the underlying causes. The margin of therapeutical gains when trialed together with placebos rarely exceeds 10%.

BiOkuris is committed to providing targeted, clinically-proven solutions for IBS patients, ensuring a complete and multifactorial effect on their physiopathology, thereby improving their quality of life.

40% of Crohn’s disease and ulcerative colitis patients with long-standing remission continue to experience IBS (Irritable Bowel Syndrome)-like symptoms.

Even during and after treatment involving biosimilars and a full control of inflammation, 40% of patients still suffer from abdominal pain, bloating, constipation, or diarrhea.

The etiology of IBS/IBS-like symptoms is multifactorial, combining hypersensitivity of the digestive tract, low-grade local inflammation, and changes in the intestinal flora with dysbiosis, increased intestinal permeability and bile acid malabsorption.

Existing and available drugs are only modestly effective, often developed to improve transit disorders and/or stool consistency via non-irritating laxatives for constipation, transit retarders for diarrhea, antispasmodics for bloating and anxiolytics.

Such ‘IBS-like symptoms’ in IBD patients need to be both comprehensively and specifically targeted to fully satisfy patients’ expectations and radically improve their quality of life.

Candida albicans is a type of yeast that can colonize any segment of the digestive tract or vagina. Its deleterious effects are well documented, ranging locally from potentially IBD-caused colitis to cutaneous-mucosal candidiasis, with vaginal candidiasis occurring in 75% of women at least once in their lives, and systemic infections that often occur in hospital, incurring significant medical and financial cost.

As the gut is the source of Candida albicans, targeting this commensal in the gut itself could reduce, even prevent, fungal infections in millions of people each year.